Ex­clu­sive: Pfiz­er, Gink­go sign R&D deal worth up to $331M to de­vel­op RNA drugs

In its lat­est Big Phar­ma deal, Gink­go Bioworks will work with Pfiz­er to de­vel­op new RNA drugs, the Boston-based syn­thet­ic bi­ol­o­gy start­up ex­clu­sive­ly told End­points News.

The two aren’t dis­clos­ing many specifics about the col­lab­o­ra­tion, but the deal will fo­cus on three RNA ther­a­peu­tic pro­grams, out­lin­ing $331 mil­lion in po­ten­tial mile­stone pay­ments, in­clud­ing an undis­closed amount up­front. Gink­go CEO Ja­son Kel­ly said it’s the lat­est ex­am­ple of ther­a­peu­tics be­ing the fastest-grow­ing area of Gink­go’s busi­ness.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER